Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Tóm tắt
Từ khóa
Tài liệu tham khảo
2005, Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology, Can J Gastroenterol, 19, 5A, 10.1155/2005/269076
1955, Cortisone in ulcerative colitis; final report on a therapeutic trial, Br Med J, 2, 1041, 10.1136/bmj.2.4947.1041
2007, Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression, Clin Gastroenterol Hepatol, 5, 103, 10.1016/j.cgh.2006.09.033
2010, Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, CD004115
1996, Distribution of mesalazine enemas in active and quiescent ulcerative colitis, Aliment Pharmacol Ther, 10, 327, 10.1111/j.0953-0673.1996.00327.x
2012, High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials, Inflamm Bowel Dis, 18, 2190, 10.1002/ibd.22939
International Salofalk Suppository OD Study Group, 2010, Clinical trial: a novel high-dose 1 g mesalamine suppository [Salofalk] once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis, Inflamm Bowel Dis, 16, 1947, 10.1002/ibd.21258
2011, A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis, Dig Dis Sci, 56, 513, 10.1007/s10620-010-1334-y
2012, Efficacy of oral vs topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis, Am J Gastroenterol, 107, 167, 10.1038/ajg.2011.410
1998, Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis, Dis Colon Rectum, 41, 93, 10.1007/BF02236902
2010, Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study, Inflamm Bowel Dis, 16, 1567, 10.1002/ibd.21193
2011, Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis—a pooled analysis, Aliment Pharmacol Ther, 34, 1115, 10.1111/j.1365-2036.2011.04840.x
1997, A double-blind comparison of oral vs rectal mesalamine vs combination therapy in the treatment of distal ulcerative colitis, Am J Gastroenterol, 92, 1867
1996, Beclomethasone dipropionate [3 mg] vs 5-aminosalicylic acid [2 g] vs the combination of both [3 mg/2 g] as retention enemas in active ulcerative proctitis, Eur J Gastroenterol Hepatol, 8, 549, 10.1097/00042737-199606000-00010
1997, Rectal corticosteroids vs alternative treatments in ulcerative colitis: a meta-analysis, Gut, 40, 775, 10.1136/gut.40.6.775
2006, Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials, Inflamm Bowel Dis, 12, 979, 10.1097/01.mib.0000231495.92013.5e
2015, Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis, Gastroenterology, 148, 740, 10.1053/j.gastro.2015.01.037
2011, Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis, Am J Gastroenterol, 106, 601, 10.1038/ajg.2011.67
2010, Mesalazine vanishing time from rectal mucosa following its topical administration, J Crohns Colitis, 4, 102, 10.1016/j.crohns.2009.08.003
2008, Mesalamine foam enema vs mesalamine liquid enema in active left-sided ulcerative colitis, Am J Gastroenterol, 103, 3106, 10.1111/j.1572-0241.2008.02152.x
International Salofalk Foam Study Group, 2007, Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs a high-volume mesalazine foam in active distal ulcerative colitis, Aliment Pharmacol Ther, 26, 1237, 10.1111/j.1365-2036.2007.03468.x
2007, Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs 5-aminosalicylic acid in mild to moderate distal ulcerative colitis, Aliment Pharmacol Ther, 26, 21, 10.1111/j.1365-2036.2007.03349.x
2016, Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, 4, CD000543
2012, Once daily oral mesalamine compared with conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis, Inflamm Bowel Dis, 18, 1785, 10.1002/ibd.23024
MOTUS study investigators, 2013, Randomised clinical trial: once- vs twice-daily prolonged-release mesalazine for active ulcerative colitis, Aliment Pharmacol Ther, 37, 767, 10.1111/apt.12266
2013, Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from Cochrane reviews, Inflamm Bowel Dis, 19, 2031
2005, Delayed-release oral mesalamine at 4.8 g/day [800 mg tablet] for the treatment of moderately active ulcerative colitis: the ASCEND II trial, Am J Gastroenterol, 100, 2478, 10.1111/j.1572-0241.2005.00248.x
2007, Effect of once- or twice-daily MTX mesalamine [SPD476] for the induction of remission of mild to moderately active ulcerative colitis, Clin Gastroenterol Hepatol, 5, 95, 10.1016/j.cgh.2006.10.025
2007, Once-daily, high-concentration MMX mesalamine in active ulcerative colitis, Gastroenterology, 132, 66, 10.1053/j.gastro.2006.10.011
2009, Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis, Inflamm Bowel Dis, 15, 1, 10.1002/ibd.20580
BETA study participating centers, 2015, Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study, Am J Gastroenterol, 110, 708, 10.1038/ajg.2015.114
2010, Oral budesonide for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, CD007698
2012, Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study, Gastroenterology, 143, 1218, 10.1053/j.gastro.2012.08.003
2014, Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study, Gut, 63, 433, 10.1136/gutjnl-2012-304258
2015, Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies, Aliment Pharmacol Ther, 41, 409, 10.1111/apt.13076
International BUC-57 Study Group, 2011, 3g mesalazine granules are superior to 9 mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial, J Crohns Colitis, 5, 129, 10.1016/j.crohns.2010.11.006
2015, OP011 Budesonide MMX® 9 mg for inducing remission in patients with mild-to-moderate ulcerative colitis not adequately controlled with oral 5-ASAs, J Crohns Colitis, 9, S7, 10.1093/ecco-jcc/jju027.011
2016, Systematic review: second-generation vs conventional corticosteroids for induction of remission in ulcerative colitis, Aliment Pharmacol Ther, 44, 1018, 10.1111/apt.13803
2005, Combined oral and enema treatment with Pentasa [mesalazine] is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study, Gut, 54, 960, 10.1136/gut.2004.060103
International Salofalk OD Study Group, 2009, Once daily vs three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial, Gut, 58, 233, 10.1136/gut.2008.154302
2014, Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2 g mesalazine dosing, J Crohns Colitis, 8, 357, 10.1016/j.crohns.2013.09.015
2014, Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: concept proved but more data needed, Clin Gastroenterol Hepatol, 12, 1894, 10.1016/j.cgh.2014.06.011
1960, An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis, Gut, 1, 217, 10.1136/gut.1.3.217
1962, Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis, Br Med J, 2, 1708, 10.1136/bmj.2.5321.1708
1962, Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone, Br Med J, 2, 441, 10.1136/bmj.2.5302.441
2003, Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study, Aliment Pharmacol Ther, 17, 1471, 10.1046/j.1365-2036.2003.01609.x
2015, Oral budesonide for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, Cd007698
2014, Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: meta-analysis of randomized controlled trials, Inflamm Bowel Dis, 20, 21, 10.1097/01.MIB.0000437495.30052.be
2012, Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients, Drugs, 72, 803, 10.2165/11632710-000000000-00000
2010, Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis, World J Gastroenterol, 16, 1908, 10.3748/wjg.v16.i15.1908
2007, Probiotics for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, CD005573
2015, Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial, Gastroenterology, 149, 102, 10.1053/j.gastro.2015.04.001
2015, Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis, Gastroenterology, 149, 110, 10.1053/j.gastro.2015.03.045
2016, 600 multi donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: a randomised placebo-controlled trial, Gastroenterology, 150, S122, 10.1016/S0016-5085(16)30517-0
2014, Helminth therapy [worms] for induction of remission in inflammatory bowel disease, Cochrane Database Syst Rev, 1, CD009400
2014, First multicenter study of modified release phosphatidylcholine ‘LT-02’ in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses, Am J Gastroenterol, 109, 1041, 10.1038/ajg.2014.104
2013, Andrographis paniculata extract [HMPL-004] for active ulcerative colitis, Am J Gastroenterol, 108, 90, 10.1038/ajg.2012.340
2016, Clinical effects of a topically applied toll-like receptor 9 agonist in active moderate-to-severe ulcerative colitis, J Crohns Colitis, 10, 1294, 10.1093/ecco-jcc/jjw103
2016, Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: a randomised, placebo-controlled, phase 2b study, J Crohns Colitis, 10, 418, 10.1093/ecco-jcc/jjv224
1974, Intensive intravenous regimen for severe attacks of ulcerative colitis, Lancet, 1, 1067
2007, Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn’s disease: record linkage studies, BMJ, 335, 1033, 10.1136/bmj.39345.714039.55
2010, Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications, Br J Surg, 97, 404, 10.1002/bjs.6874
2013, Prolonged preoperative hospital stay is a risk factor for complications after emergency colectomy for severe colitis, Colorectal Dis, 15, 1392, 10.1111/codi.12328
Epidemiology and Natural History Task Force of the International Organization of the Study of Inflammatory Bowel Disease, 2013, A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease, Inflamm Bowel Dis, 19, 2001
Canadian Association of Gastroenterology Severe Ulcerative Colitis Consensus Group, 2012, Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements, Am J Gastroenterol, 107, 179, 10.1038/ajg.2011.386
2013, Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit, Aliment Pharmacol Ther, 38, 935, 10.1111/apt.12473
1990, High-dose methylprednisolone in the treatment of active ulcerative colitis, J Clin Gastroenterol, 12, 40, 10.1097/00004836-199002000-00011
2007, Continuous infusion vs bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial, Am J Gastroenterol, 102, 601, 10.1111/j.1572-0241.2006.01007.x
2001, Intravenous cyclosporine vs intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis, Gastroenterology, 120, 1323, 10.1053/gast.2001.23983
2003, Randomized, double-blind comparison of 4 mg/kg vs 2 mg/kg intravenous cyclosporine in severe ulcerative colitis, Gastroenterology, 125, 1025
2001, Outcome of cytomegalovirus infections in patients with inflammatory bowel disease, Am J Gastroenterol, 96, 2137, 10.1111/j.1572-0241.2001.03949.x
2004, Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome, J Med Microbiol, 53, 1155, 10.1099/jmm.0.45629-0
2008, Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy, Inflamm Bowel Dis, 14, 1373, 10.1002/ibd.20498
2016, Risk factors and clinical outcomes associated with cytomegalovirus colitis in patients with acute severe ulcerative colitis, Inflamm Bowel Dis, 22, 912, 10.1097/MIB.0000000000000675
European Crohn’s and Colitis Organisation [ECCO], 2014, Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease, J Crohns Colitis, 8, 443, 10.1016/j.crohns.2013.12.013
2008, Clostridium difficile and inflammatory bowel disease, Inflamm Bowel Dis, 14, 1432, 10.1002/ibd.20500
2007, Impact of Clostridium difficile on inflammatory bowel disease, Clin Gastroenterol Hepatol, 5, 345, 10.1016/j.cgh.2006.12.028
2008, A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients, Am J Gastroenterol, 103, 1443, 10.1111/j.1572-0241.2007.01780.x
2011, Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease, Aliment Pharmacol Ther, 33, 1322, 10.1111/j.1365-2036.2011.04661.x
2014, Clostridium difficile infection worsens the prognosis of ulcerative colitis, Can J Gastroenterol Hepatol, 28, 373, 10.1155/2014/914303
2012, Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis, Aliment Pharmacol Ther, 36, 1032, 10.1111/apt.12073
2013, Clostridium difficile infection in the inflammatory bowel disease patient, Inflamm Bowel Dis, 19, 194, 10.1002/ibd.22964
2012, Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis, J Crohns Colitis, 6, 330, 10.1016/j.crohns.2011.09.005
2014, Antibiotics for Treatment of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease, Antimicrob Agents Chemother, 58, 5054, 10.1128/AAC.02606-13
2014, Microbial composition analysis of Clostridium difficile infections in an ulcerative colitis patient treated with multiple fecal microbiota transplantations, J Crohns Colitis, 8, 1133, 10.1016/j.crohns.2014.01.020
2009, Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection, Clin Gastroenterol Hepatol, 7, 981, 10.1016/j.cgh.2009.05.031
European Crohn’s and Colitis Organisation [ECCO], 2009, European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease, J Crohns Colitis, 3, 47, 10.1016/j.crohns.2009.02.010
2011, Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study, Gut, 60, 937, 10.1136/gut.2010.228585
2010, Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study, Lancet, 375, 657, 10.1016/S0140-6736(09)61963-2
2014, Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology, Gastroenterology, 146, 835, 10.1053/j.gastro.2014.01.042
European Crohn’s and Colitis Organisation, 2016, The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease, J Crohns Colitis, 10, 239, 10.1093/ecco-jcc/jjv213
1993, Enteral vs parenteral nutrition as adjunct therapy in acute ulcerative colitis, Am J Gastroenterol, 88, 227
1986, Controlled trial of bowel rest in the treatment of severe acute colitis, Gut, 27, 481, 10.1136/gut.27.5.481
2003, A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management, Am J Gastroenterol, 98, 2363, 10.1111/j.1572-0241.2003.07696.x
2006, Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease, Clin Gastroenterol Hepatol, 4, 196, 10.1016/S1542-3565(05)00980-8
2009, Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?, Eur J Clin Pharmacol, 65, 963, 10.1007/s00228-009-0719-3
2015, Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease, Scand J Gastroenterol, 50, 255, 10.3109/00365521.2014.966753
2012, Narcotic use for inflammatory bowel disease and risk factors during hospitalization, Inflamm Bowel Dis, 18, 869, 10.1002/ibd.21806
1986, Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis, Gut, 27, 1210, 10.1136/gut.27.10.1210
1994, Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis, Am J Gastroenterol, 89, 43
2001, A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis, Scand J Gastroenterol, 36, 971, 10.1080/00365520120413
European Crohn’s and Colitis Organisation [ECCO], 2015, European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases, J Crohns Colitis, 9, 211, 10.1093/ecco-jcc/jju009
2011, Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers, Gut, 60, 3, 10.1136/gut.2010.216895
International Inflammatory Bowel Disease Genetics Consortium, 2016, Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study, Lancet, 387, 156, 10.1016/S0140-6736(15)00465-1
1998, Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis, Eur J Gastroenterol Hepatol, 10, 831, 10.1097/00042737-199810000-00003
UK IBD Audit Steering Group, 2016, Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using UK IBD audit data, Aliment Pharmacol Ther, 43, 1132, 10.1111/apt.13614
2004, Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment, Dig Liver Dis, 36, 461, 10.1016/j.dld.2003.12.017
1996, Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis, Lancet, 347, 1731, 10.1016/S0140-6736(96)90808-9
2000, Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis, Aliment Pharmacol Ther, 14, 273, 10.1046/j.1365-2036.2000.00705.x
1994, Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity, Dig Dis Sci, 39, 1550
2015, Association between the ulcerative colitis endoscopic index of severity [UCEIS] and outcomes in acute severe ulcerative colitis, J Crohns Colitis, 9, 376, 10.1093/ecco-jcc/jjv047
2004, Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery, Aliment Pharmacol Ther, 19, 1079, 10.1111/j.1365-2036.2004.01945.x
1994, Cyclosporine in severe ulcerative colitis refractory to steroid therapy, N Engl J Med, 330, 1841, 10.1056/NEJM199406303302601
1999, Intravenous cyclosporin in ulcerative colitis: a five-year experience, Am J Gastroenterol, 94, 1587, 10.1111/j.1572-0241.1999.01149.x
2006, Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis, Clin Gastroenterol Hepatol, 4, 760, 10.1016/j.cgh.2006.04.001
2016, Infliximab vs ciclosporin for steroid-resistant acute severe ulcerative colitis [CONSTRUCT]: a mixed methods, open-label, pragmatic randomised trial, Lancet Gastroenterol Hepatol, 1, 15, 10.1016/S2468-1253(16)30003-6
2005, Cyclosporine A for induction of remission in severe ulcerative colitis, Cochrane Database Syst Rev, CD004277
2005, Ciclosporin use in acute ulcerative colitis: a long-term experience, Eur J Gastroenterol Hepatol, 17, 79, 10.1097/00042737-200501000-00016
2011, Cyclosporine is safe and effective in patients with severe ulcerative colitis, J Clin Gastroenterol, 45, 107, 10.1097/MCG.0b013e3181e883dd
2010, Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis, J Gastroenterol Hepatol, 25, 494, 10.1111/j.1440-1746.2009.06119.x
2010, Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines, J Crohns Colitis, 4, 398, 10.1016/j.crohns.2010.01.001
2006, A randomised dose finding study of oral tacrolimus [FK506] therapy in refractory ulcerative colitis, Gut, 55, 1255, 10.1136/gut.2005.081794
2012, Double-blind, placebo-controlled trial of oral tacrolimus [FK506] in the management of hospitalized patients with steroid-refractory ulcerative colitis, Inflamm Bowel Dis, 18, 803, 10.1002/ibd.21853
2016, Efficacy and safety of tacrolimus therapy for active ulcerative colitis; a systematic review and meta-analysis, J Crohns Colitis, 10, 484, 10.1093/ecco-jcc/jjv221
2006, Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease a long-term follow-up, Am J Gastroenterol, 101, 1048, 10.1111/j.1572-0241.2006.00524.x
2005, Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study, Gastroenterology, 128, 1805, 10.1053/j.gastro.2005.03.003
2001, Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study, Inflamm Bowel Dis, 7, 83, 10.1097/00054725-200105000-00001
Scottish Society of Gastroenterology Infliximab Group, 2007, A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis, Aliment Pharmacol Ther, 26, 411, 10.1111/j.1365-2036.2007.03383.x
2010, Clinical trial: colectomy after rescue therapy in ulcerative colitis—3-year follow-up of the Swedish-Danish controlled infliximab study, Aliment Pharmacol Ther, 32, 984, 10.1111/j.1365-2036.2010.04435.x
Swedish Organization for the Study of Inflammatory Bowel Disease [SOIBD], 2013, Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients, Aliment Pharmacol Ther, 38, 377, 10.1111/apt.12387
2006, Infliximab for hospitalized patients with severe ulcerative colitis, J Clin Gastroenterol, 40, 476, 10.1097/00004836-200607000-00004
2007, Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006, Aliment Pharmacol Ther, 25, 1055, 10.1111/j.1365-2036.2007.03300.x
2007, Predictors of early response to infliximab in patients with ulcerative colitis, Inflamm Bowel Dis, 13, 123, 10.1002/ibd.20054
2014, Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy, Intern Med J, 44, 464, 10.1111/imj.12397
2013, Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience, World J Gastroenterol, 19, 1091, 10.3748/wjg.v19.i7.1091
2011, Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals, J Crohns Colitis, 5, 28, 10.1016/j.crohns.2010.09.004
Italian Group for the study of Inflammatory Bowel Disease [IG-IBD], 2014, Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy, J Crohns Colitis, 8, 852, 10.1016/j.crohns.2014.01.006
2016, Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis, Clin Gastroenterol Hepatol, 14, 251, 10.1016/j.cgh.2015.10.029
2015, Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis, Gastroenterology, 149, 350, 10.1053/j.gastro.2015.04.016
2016, Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis, Aliment Pharmacol Ther, 43, 1293, 10.1111/apt.13631
2007, Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up, Aliment Pharmacol Ther, 26, 747, 10.1111/j.1365-2036.2007.03415.x
2015, An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis, Clin Gastroenterol Hepatol, 13, 330, 10.1016/j.cgh.2014.07.041
2014, Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis, Inflamm Bowel Dis, 20, 1368, 10.1097/MIB.0000000000000115
2012, Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial, Lancet, 380
2013, Infliximab vs cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis, Int J Colorectal Dis, 28, 287, 10.1007/s00384-012-1602-8
2014, Length of hospital stay and associated hospital costs with infliximab vs cyclosporine in severe ulcerative colitis, Eur J Gastroenterol Hepatol, 26, 1240, 10.1097/MEG.0000000000000187
2016, The next wave of biological agents for the treatment of IBD: evidence from Cochrane reviews, Inflamm Bowel Dis, 22, 1737, 10.1097/MIB.0000000000000808
2009, Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis, Inflamm Bowel Dis, 15, 1062, 10.1002/ibd.20863
2001, Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications, Dis Colon Rectum, 44, 1436, 10.1007/BF02234594
2004, Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy, Am J Gastroenterol, 99, 878, 10.1111/j.1572-0241.2004.04148.x
2008, Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications, J Gastrointest Surg, 12, 1730, 10.1007/s11605-008-0630-8
2010, Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis, Aliment Pharmacol Ther, 31, 486, 10.1111/j.1365-2036.2009.04204.x
2015, Anti-tumor necrosis factor-α antibody therapy management before and after intestinal surgery for inflammatory bowel disease: a CCFA position paper, Inflamm Bowel Dis, 21, 2658, 10.1097/MIB.0000000000000603
2016, Preoperative anti-tumor necrosis factor therapy in patients with ulcerative colitis is not associated with an increased risk of infectious and noninfectious complications after ileal pouch-anal anastomosis, Inflamm Bowel Dis, 22, 2442, 10.1097/MIB.0000000000000919
2013, Surgical outcomes in steroid refractory acute severe ulcerative colitis: the impact of rescue therapy, Colorectal Dis, 15, 374, 10.1111/j.1463-1318.2012.03188.x
2015, Systematic review: sequential rescue therapy in severe ulcerative colitis: do the benefits outweigh the risks?, Inflamm Bowel Dis, 21, 1683, 10.1097/MIB.0000000000000350
2014, Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study, Aliment Pharmacol Ther, 39, 949, 10.1111/apt.12688
2005, Pattern and outcome of severe ulcerative colitis: 15 year data, Gut, 54, A155
2008, Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis, Am J Gastroenterol, 103, 637, 10.1111/j.1572-0241.2007.01653.x
2000, Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis, Aliment Pharmacol Ther, 14, 155, 10.1046/j.1365-2036.2000.00697.x
1985, Intensive intravenous treatment of ulcerative colitis, Gastroenterology, 89, 1005, 10.1016/0016-5085(85)90201-X
1994, A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis, Gastroenterology, 106, 1429, 10.1016/0016-5085(94)90394-8
2008, Rectal tacrolimus in the treatment of resistant ulcerative proctitis, Aliment Pharmacol Ther, 28, 1214, 10.1111/j.1365-2036.2008.03841.x
2009, Local application of tacrolimus in distal colitis: feasible and safe, Inflamm Bowel Dis, 15, 193, 10.1002/ibd.20644
2010, Infliximab for refractory ulcerative proctitis, Aliment Pharmacol Ther, 31, 1178, 10.1111/j.1365-2036.2010.04293.x
2013, Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis—experience in 130 patients, Aliment Pharmacol Ther, 37, 129, 10.1111/apt.12118
1997, Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial, Gut, 40, 485, 10.1136/gut.40.4.485
1996, Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group, Dig Dis Sci, 41, 2254, 10.1007/BF02071409
1998, Lidocaine enemas for intractable distal ulcerative colitis: efficacy and safety, Gastroenterology, 114, A1073, 10.1016/S0016-5085(98)84366-7
2003, Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis, N Engl J Med, 349, 350, 10.1056/NEJMoa013136
2002, Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine vs oral mesalamine, Can J Gastroenterol, 16, 293, 10.1155/2002/307218
1989, Safety and efficacy of acetarsol suppositories in unresponsive proctitis, Aliment Pharmacol Ther, 3, 553, 10.1111/j.1365-2036.1989.tb00247.x
2013, Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis, Aliment Pharmacol Ther, 38, 284, 10.1111/apt.12369
2009, Appendicectomy as a therapy for ulcerative proctitis, Am J Gastroenterol, 104, 2476, 10.1038/ajg.2009.388
2015, The ACCURE-trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicenter trial [NTR2883] and the ACCURE-UK trial: a randomised external pilot trial [ISRCTN56523019], BMC Surg, 15, 30, 10.1186/s12893-015-0017-1
2011, Appendicectomy as a potential therapy for refractory ulcerative proctitis, Aliment Pharmacol Ther, 34, 257, 10.1111/j.1365-2036.2011.04705.x
2012, The effect of appendectomy on the course of ulcerative colitis: a systematic review, Colorectal Dis, 14, 545, 10.1111/j.1463-1318.2011.02600.x
2006, Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis, Gut, 55, 47, 10.1136/gut.2005.068809
2010, Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis, Inflamm Bowel Dis, 16, 613, 10.1002/ibd.21083
2005, Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, 353, 2462, 10.1056/NEJMoa050516
2013, Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission, Inflamm Bowel Dis, 19, 1065, 10.1097/MIB.0b013e3182802909
2012, Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 142, 257, 10.1053/j.gastro.2011.10.032
PURSUIT-Maintenance Study Group, 2014, Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 146, 96, 10.1053/j.gastro.2013.06.010
2014, Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 146, 85, 10.1053/j.gastro.2013.05.048
2011, Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial, J Crohns Colitis, 5, 13
2015, Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed, Aliment Pharmacol Ther, 41, 613, 10.1111/apt.13083
GEMINI 1 Study Group, 2013, Vedolizumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med, 369, 699, 10.1056/NEJMoa1215734
Vedolizumab Germany Consortium, 2016, Vedolizumab induction therapy for inflammatory bowel disease in clinical practice–a nationwide consecutive German cohort study, Aliment Pharmacol Ther, 43, 1090, 10.1111/apt.13594
European Crohn’s and Colitis Organisation; Groupe d’Étude Thérapeutique des Affections Inflammatoires Digestives, 2016, Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis, Gastroenterology, 150, 380, 10.1053/j.gastro.2015.10.050
2014, Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids, J Crohns Colitis, 8, 1523, 10.1016/j.crohns.2014.06.010
2013, 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants, Inflamm Bowel Dis, 19, 1700, 10.1097/MIB.0b013e318281f2b7
2016, Tacrolimus vs anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study, Aliment Pharmacol Ther, 43, 705, 10.1111/apt.13531
2016, Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe ulcerative colitis: results from two phase 3 randomized controlled trials, Gastroenterology, 150, S157, 10.1016/S0016-5085(16)30622-9
TOUCHSTONE Study Group, 2016, Ozanimod induction and maintenance treatment for ulcerative colitis, N Engl J Med, 374, 1754, 10.1056/NEJMoa1513248
Study A3921063 Investigators, 2012, Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis, N Engl J Med, 367, 616, 10.1056/NEJMoa1112168
2006, Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, 3, CD005112
2011, Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial, Gut, 60, 780, 10.1136/gut.2010.221127
2011, 52-week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants, J Crohns Colitis, 5, 10
2010, Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort, Aliment Pharmacol Ther, 32, 522, 10.1111/j.1365-2036.2010.04380.x
SONIC Study Group, 2010, Infliximab, azathioprine, or combination therapy for Crohn’s disease, N Engl J Med, 362, 1383, 10.1056/NEJMoa0904492
2014, Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis, Gastroenterology, 146, 392, 10.1053/j.gastro.2013.10.052
2014, Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD, Inflamm Bowel Dis, 20, 2292, 10.1097/MIB.0000000000000208
2008, Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn’s disease: a single-center experience, Inflamm Bowel Dis, 14, 7
2008, Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis, Aliment Pharmacol Ther, 28, 589, 10.1111/j.1365-2036.2008.03764.x
2013, A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study, Ann Rheum Dis, 72, 1613, 10.1136/annrheumdis-2012-203090
2013, A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study, Ann Rheum Dis, 72, 1605, 10.1136/annrheumdis-2012-203091
2015, The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?, Expert Rev Gastroenterol Hepatol, 9, 27, 10.1586/17474124.2015.1091307
2015, Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13, Expert Rev Gastroenterol Hepatol, 9, 5, 10.1586/17474124.2015.1091304
2015, The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13, Expert Rev Gastroenterol Hepatol, 9, 17, 10.1586/17474124.2015.1091306
2015, Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis—experiences from a single center, Expert Opin Biol Ther, 15, 1257, 10.1517/14712598.2015.1064893
2016, Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort, J Crohns Colitis, 10, 133, 10.1093/ecco-jcc/jjv220
2017, ECCO position statement on the use of biosimilars for inflammatory bowel disease─an update, J Crohns Colitis, 11, 26, 10.1093/ecco-jcc/jjw198
2012, Mucosal healing with infliximab: results from the active ulcerative colitis trials, Gastroenterol Hepatol, 8, 117
2011, Review article: defining remission in ulcerative colitis, Aliment Pharmacol Ther, 34, 113, 10.1111/j.1365-2036.2011.04701.x
2014, Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis, Ann Intern Med, 160, 704, 10.7326/M13-2403
2016, Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, CD000478
2015, The impact of biological interventions for ulcerative colitis on health-related quality of life, Cochrane Database Syst Rev, CD008655
2011, Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis, Gastroenterology, 141, 1194, 10.1053/j.gastro.2011.06.054
2016, Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 14, 1245, 10.1016/j.cgh.2016.01.015
2016, Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: a meta-analysis, Inflamm Bowel Dis, 22, 1859, 10.1097/MIB.0000000000000816
1989, Ulcerative colitis in remission: it is possible to predict the risk of relapse?, Digestion, 44, 217, 10.1159/000199914
2001, Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis, Gastroenterology, 120, 13, 10.1053/gast.2001.20912
2003, Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study, Am J Gastroenterol, 98, 2203, 10.1111/j.1572-0241.2003.07717.x
2006, Life events and inflammatory bowel disease relapse: a prospective study of patients enrolled in remission, Am J Gastroenterol, 101, 775, 10.1111/j.1572-0241.2006.00476.x
1991, Microscopic activity in ulcerative colitis: what does it mean?, Gut, 32, 174, 10.1136/gut.32.2.174
1966, Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets, Am J Dig Dis, 11, 847, 10.1007/BF02233941
2016, Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study, Am J Gastroenterol, 111, 685, 10.1038/ajg.2016.50
2003, Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis, Am J Med, 114, 39, 10.1016/S0002-9343(02)01383-9
2001, The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study, Gastroenterology, 121, 255, 10.1053/gast.2001.26279
IBSEN Study Group, 2009, Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort [IBSEN Study], Scand J Gastroenterol, 44, 431, 10.1080/00365520802600961
2015, Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies, J Crohns Colitis, 9, 156, 10.1093/ecco-jcc/jju016
2009, Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol, Aliment Pharmacol Ther, 30, 908, 10.1111/j.1365-2036.2009.04117.x
1988, Comparison of delayed-release 5-aminosalicylic acid [mesalazine] and sulfasalazine as maintenance treatment for patients with ulcerative colitis, Gastroenterology, 94, 1383, 10.1016/0016-5085(88)90677-4
2009, Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis, Clin Gastroenterol Hepatol, 7, 762, 10.1016/j.cgh.2009.04.004
2010, Once-daily dosing of delayed-release oral mesalamine [400 mg tablet] is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis, Gastroenterology, 138, 1286, 10.1053/j.gastro.2009.12.054
1995, Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group, Dig Dis Sci, 40, 296, 10.1007/BF02065413
1973, A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine [Salazopyrin], Gut, 14, 923, 10.1136/gut.14.12.923
1965, Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis, Lancet, 285, 185, 10.1016/S0140-6736(65)90972-4
2008, Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis, Gut, 57, 893, 10.1136/gut.2007.138248
2012, Once-daily MMX[®] mesalamine for endoscopic maintenance of remission of ulcerative colitis, Am J Gastroenterol, 107, 1064, 10.1038/ajg.2012.103
1998, Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group, Gastroenterology, 114, 15, 10.1016/S0016-5085(98)70627-4
1994, Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis, Dis Colon Rectum, 37, 58, 10.1007/BF02047216
1998, Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study, Gut, 42, 195, 10.1136/gut.42.2.195
1998, Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group, Am J Gastroenterol, 93, 799, 10.1111/j.1572-0241.1998.228_a.x
1997, Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study, Am J Gastroenterol, 92, 1143
1994, The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis, Gastroenterology, 106, A736
1990, 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial, Am J Gastroenterol, 85, 1079
2000, Long-term use of mesalamine [Rowasa] suppositories in remission maintenance of ulcerative proctitis, Am J Gastroenterol, 95, 1749, 10.1111/j.1572-0241.2000.02185.x
2012, Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, 11, CD004118
2007, Effect of weekend 5-aminosalicylic acid [mesalazine] enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study, Inflamm Bowel Dis, 13, 1115, 10.1002/ibd.20158
1997, Oral or rectal administration of drugs in IBD?, Aliment Pharmacol Ther, 11, 999, 10.1111/j.1365-2036.1997.tb00001.x
2012, Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing, J Crohns Colitis, 6, 476, 10.1016/j.crohns.2011.10.006
2005, Comparison of two different daily dosages [2.4 vs 1.2 g] of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study, Aliment Pharmacol Ther, 21, 1111, 10.1111/j.1365-2036.2005.02458.x
2012, Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, 10, CD000544
Toronto Ulcerative Colitis Consensus Group, 2015, Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus, Gastroenterology, 148, 1035, 10.1053/j.gastro.2015.03.001
2006, Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis, Aliment Pharmacol Ther, 24, 37, 10.1111/j.1365-2036.2006.03058.x
International Salofalk OD Study Group, 2011, Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis, Aliment Pharmacol Ther, 33, 313, 10.1111/j.1365-2036.2010.04537.x
2001, Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis, Am J Gastroenterol, 96, 2929, 10.1111/j.1572-0241.2001.04683.x
2003, A pilot feasibility study of once daily vs conventional dosing mesalamine for maintenance of ulcerative colitis, Clin Gastroenterol Hepatol, 1, 170, 10.1016/S1542-3565(03)70032-9
1992, Randomised controlled trial of azathioprine withdrawal in ulcerative colitis, BMJ, 305, 20, 10.1136/bmj.305.6844.20
1974, Azathioprine in ulcerative colitis: final report on controlled therapeutic trial, Br Med J, 4, 627, 10.1136/bmj.4.5945.627
2002, The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis, J Gastroenterol, 37, 270, 10.1007/s005350200034
2003, Azathioprine vs sulfasalazine in maintenance of remission in severe ulcerative colitis, Indian J Gastroenterol, 22, 79
2000, 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease, Eur J Gastroenterol Hepatol, 12, 1227, 10.1097/00042737-200012110-00010
2009, Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal, Am J Gastroenterol, 104, 2760, 10.1038/ajg.2009.410
1996, The long-term outcome of ulcerative colitis treated with 6-mercaptopurine, Am J Gastroenterol, 91, 1711
2002, The efficacy of methotrexate for maintaining remission in inflammatory bowel disease, Aliment Pharmacol Ther, 16, 693, 10.1046/j.1365-2036.2002.01227.x
1997, Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis, J Clin Gastroenterol, 25, 330, 10.1097/00004836-199707000-00007
1990, The role of azathioprine in the management of ulcerative colitis, Dis Colon Rectum, 33, 374, 10.1007/BF02156261
2000, Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience, Digestion, 62, 249, 10.1159/000007823
1990, The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis, Am J Gastroenterol, 85, 717
2002, The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review, Gut, 50, 485, 10.1136/gut.50.4.485
2015, Prognosis of patients with ulcerative colitis in sustained remission after thiopurines withdrawal, Inflamm Bowel Dis, 21, 1564, 10.1097/MIB.0000000000000400
1996, Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses, Dig Dis Sci, 41, 2471, 10.1007/BF02100145
2007, Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study, BMC Gastroenterol, 7, 13, 10.1186/1471-230X-7-13
1996, Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis, Am J Gastroenterol, 91, 2498
2008, Long-term outcome after infliximab for refractory ulcerative colitis, J Crohns Colitis, 2, 219, 10.1016/j.crohns.2008.03.004
2014, Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis, Gastroenterology, 146, 110, 10.1053/j.gastro.2013.09.032
2014, Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3, Am J Gastroenterol, 109, 1771, 10.1038/ajg.2014.242
2016, Maintenance of Efficacy and Continuing Safety of Golimumab for Active ulcerative colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year, Clin Transl Gastroenterol, 7, e168, 10.1038/ctg.2016.24
2014, Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases, Clin Gastroenterol Hepatol, 12, 80, 10.1016/j.cgh.2013.07.010
2016, Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis, Therap Adv Gastroenterol, 9, 548, 10.1177/1756283X16643242
2015, Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases, Expert Opin Biol Ther, 15, 1107, 10.1517/14712598.2015.1044434
2015, Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease, Gastroenterology, 148, 1320, 10.1053/j.gastro.2015.02.031
2015, Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab, Clin Gastroenterol Hepatol, 13, 522, 10.1016/j.cgh.2014.07.029
2013, Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease [IBD]: a meta-analysis, Am J Gastroenterol, 108, 40, 10.1038/ajg.2012.363
2003, Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease, N Engl J Med, 348, 601, 10.1056/NEJMoa020888
2006, Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease, Clin Gastroenterol Hepatol, 4, 1248, 10.1016/j.cgh.2006.06.025
2008, Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial, Gastroenterology, 134, 1861, 10.1053/j.gastro.2008.03.004
2016, Long-term efficacy of vedolizumab for ulcerative colitis, J Crohns Colitis
2017, Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists, Clin Gastroenterol Hepatol, 15, 229, 10.1016/j.cgh.2016.08.044
GEMINI 1 Study Group, 2013, Vedolizumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med, 369, 699, 10.1056/NEJMoa1215734
1997, Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis, Aliment Pharmacol Ther, 11, 853, 10.1046/j.1365-2036.1997.00225.x
1999, Non-pathogenic Escherichia coli vs mesalazine for the treatment of ulcerative colitis: a randomised trial, Lancet, 354, 635, 10.1016/S0140-6736(98)06343-0
2004, Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine, Gut, 53, 1617, 10.1136/gut.2003.037747
2008, Probiotic Escherichia coli Nissle 1917 [EcN] for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study, Z Gastroenterol, 46, 874, 10.1055/s-2008-1027463
2003, Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis, J Am Coll Nutr, 22, 56, 10.1080/07315724.2003.10719276
2006, Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis, Aliment Pharmacol Ther, 23, 1567, 10.1111/j.1365-2036.2006.02927.x
2011, Probiotics for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, CD007443
1998, Ciprofloxacin as a treatment for ulcerative colitis not yet, Gastroenterology, 115, 1289, 10.1016/S0016-5085(98)70104-0
1989, A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis, J Clin Gastroenterol, 11, 392, 10.1097/00004836-198908000-00008
1996, Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial, Gastroenterology, 110, 1416, 10.1053/gast.1996.v110.pm8613046
2009, Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine, Aliment Pharmacol Ther, 30, 614, 10.1111/j.1365-2036.2009.04073.x
2001, Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study, Am J Gastroenterol, 96, 793, 10.1111/j.1572-0241.2001.03624.x
2015, Methotrexate for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, 8, CD007560
1973, The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment. A double-blind trial on patients asymptomatic for one year, Scand J Gastroenterol, 8, 71, 10.1080/00365521.1973.12096672
1999, Is maintenance therapy always necessary for patients with ulcerative colitis in remission?, Aliment Pharmacol Ther, 13, 373, 10.1046/j.1365-2036.1999.00473.x
2015, Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease, Gastroenterology, 149, 1716, 10.1053/j.gastro.2015.08.055
2009, Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review, Curr Drug Targets, 11, 156
2012, Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies, Inflamm Bowel Dis, 18, 201, 10.1002/ibd.21697
2016, Discontinuation of infliximab in patients with ulcerative colitis is associated with increased risk of relapse: a multinational retrospective cohort study, Clin Gastroenterol Hepatol, 14, 1426, 10.1016/j.cgh.2016.05.044
2016, The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis, Am J Gastroenterol, 111, 632, 10.1038/ajg.2016.54
2017, European Crohn’s and Colitis Organisation topical review on transitional care in inflammatory bowel disease, J Crohns Colitis